Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Partnership
Avanzanite Bioscience Expands Partnership with Advicenne in Additional European Countries
Details : Under the partnership, Avanzanite gains commercialization and distribution rights into three additional European countries, for Sibnayal (potassium citrate and potassium bicarbonate), the first approved medicinal product in Europe for distal Renal Tubula...
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sibnayal (potassium citrate) is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough.
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 28, 2023
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : FrostPharma AB
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, FrostPharma will receive exclusive marketing rights to Sibnayal™ for the treatment of dRTA. Advicenne will receive a transfer price for the sale of its product and royalties for an amount significantly higher than 50% ...
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : FrostPharma AB
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of DRTA
Details : Sibnayal™ is a multi-particulate formulation in 2mm granules, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients.
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2021
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Advicenne’s lead product, ADV7103, is developed as a multi-particulate formulation in 2mm microtablets, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients to ease its administration.
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2021
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ADV7103/Sibnayal (potassium citrate) becomes the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2021
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?